Pate: 8/24/2021	
our Name: Xueyu Zhan	
Nanuscript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN	
/lanuscript number (if known): APM-21-2065	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		I a	L. 04070644
		National Natural Science Foundation of China	No. 81970641
		Sichuan Medical Research Project	S18040
		Science and Technology project of the heath	19PJ132
		planning Committee  the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for	2019YFS0538
		Kidney Diseases	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
4	Consulting rees	xNone	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
0	pending	^NOTIE	
	F		
9	Participation on a Data	XNone	
5	Safety Monitoring Board or	^_INUITE	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descipt of a miles	V Non-	
12	Receipt of equipment, materials, drugs, medical	X_None	
	materials, urugs, medical		

	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538).

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	8/24/2021
Your I	Name: Fei Deng
Manu	script Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manu	script number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National Natural Science Foundation of China Sichuan Medical Research	No. 81970641 S18040
		Sichuan Medical Research	\$18040
			1.518040
		Decidet	5253.5
		Project	1001122
		Science and Technology	19PJ132
		project of the heath	
		planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		the National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
3	Noyalties of ficerises	XNone	
4	Canadhinataa	V. Name	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
	-		
8	Patents planned, issued or	XNone	
	pending		
Q	Participation on a Data	Y None	
3		XNOTIE	
4.5			
10		XNone	
	in other board, society,		
9	Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role	XNone  XNone	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered	every question and	d have not altered	the wording of	any of the qu	iestions o	n this
	form.							

Date:	8/24/2021
Your N	ame: Amanda Y. Wang
Manus	cript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manus	cript number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National Natural Science	No. 81970641
		Foundation of China	
		Sichuan Medical Research	S18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	20131130330
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
	,		
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
	-		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
9	Safety Monitoring Board or		
	Advisory Board		
10		X None	
10	Leadership or fiduciary role in other board, society,	XNone	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered e	every question and	have not altered t	the wording of an	y of the questic	ons on this
	form.						

Date:	8/24/2021
Your I	Name: Qin Chen
Manu	script Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manu	script number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National National Colon	N= 01070C41
		National Natural Science Foundation of China	No. 81970641
			510040
		Sichuan Medical Research	S18040
		Project	4001422
		Science and Technology	19PJ132
		project of the heath	
		planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
	221134111115 1223		
5	Payment or honoraria for	X None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
		V. None	
6	Payment for expert	XNone	
	testimony		
_		V N	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
	, kending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	· · · · · · · · · · · · · · · · · · ·	1	<u> </u>

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered e	every question and	have not altered t	the wording of ar	ny of the quest	tions on this
	form.						

Date: 8/24/20	21
Your Name: Yo	ngjing Du
<b>Manuscript Titl</b>	e: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manuscript nui	mber (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning or the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National Natural Science	No. 81970641
		Foundation of China	
		Sichuan Medical Research	S18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	20131130336
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
	5 1	Australia.	
3	Royalties or licenses	XNone	
4	Consulting food	V. None	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
,	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8			
1	Patents planned, issued or	XNone	
1	Patents planned, issued or pending	XNone	
	I -	XNone	
g	pending		
9	pending  Participation on a Data	XNone	
9	pending  Participation on a Data  Safety Monitoring Board or		
	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
9	pending  Participation on a Data  Safety Monitoring Board or		

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered e	every question and	have not altered t	the wording of an	y of the questic	ons on this
	form.						

Date:	8/24/2021
Your N	ame: QiuXia Wang
Manus	cript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manus	cript number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National Natural Science	No. 81970641
		Foundation of China	
		Sichuan Medical Research	S18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	20131130330
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship  RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
	,		
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
	_		
	lectures, presentations,		
	speakers bureaus,		
	speakers bureaus, manuscript writing or		
	speakers bureaus, manuscript writing or educational events	Y None	
6	speakers bureaus, manuscript writing or educational events Payment for expert	XNone	
	speakers bureaus, manuscript writing or educational events	XNone	
	speakers bureaus, manuscript writing or educational events Payment for expert testimony		
6	speakers bureaus, manuscript writing or educational events Payment for expert	XNone	
6	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending		
6	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending		
6	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending		
6	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel		
7	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending	XNone	
7	speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or	XNone	
6 7 8	speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending	XNone	
7	speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data	XNone	
6 7 8	speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or	XNone	
6 7 8	speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board	XNoneXNoneXNone	
6 7 8	speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or	XNoneXNoneXNone	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered	every question and	l have not altered	the wording of	any of the q	uestions o	n this
	form.							

Date: 8/24/2021	
Your Name: Xiang Zhong	
Manuscript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN	
Manuscript number (if known): APM-21-2065	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National Natural Science	No. 81970641
		Foundation of China	
		Sichuan Medical Research	S18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	20131130336
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
	2 1	Australia.	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
4	Consulting lees		
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8			
١٥	Patents planned, issued or	XNone	
	Patents planned, issued or pending	XNone	
3	-	XNone	
9	-	XNone	
	pending		
	pending  Participation on a Data		
	pending  Participation on a Data  Safety Monitoring Board or		
9	pending  Participation on a Data Safety Monitoring Board or Advisory Board	XNone	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered e	every question and	have not altered t	the wording of an	y of the questic	ons on this
	form.						

Date:	<u>8/24/2021</u>
Your N	ame: Ping Zhang
Manus	cript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manus	cript number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National National Calaman	No. 91070041
		National Natural Science Foundation of China	No. 81970641
			C10040
		Sichuan Medical Research	\$18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath	
		planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
	,		
4	Consulting fees	X None	
4	Consulting rees	XNone	
-	Dayway tankay hay ayaris fay	V Nava	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
0	Datanta plannad issued ==	V None	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	in other board, society,	1	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered even	ery question and	have not altered tl	he wording of any	of the questions	on this
	form.						

Date: 8/24/2021	
Your Name: We	ei Wang
<b>Manuscript Title:</b>	HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manuscript numb	er (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		Notional Natural Calaria	No. 91070641
		National Natural Science Foundation of China	No. 81970641
			C10040
		Sichuan Medical Research	\$18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath	
		planning Committee	2040VEC0E20
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
٥	pending	^_None	
	Penung		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	, ,,	1	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered e	every question and	have not altered t	the wording of an	y of the questic	ons on this
	form.						

Date:	8/24/2021
Your I	Name: Shasha Chen
Manu	script Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manu	script number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National Natural Science	No. 81970641
		Foundation of China	
		Sichuan Medical Research	S18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	20131130330
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship  RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
	,		
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
	-	X	
	lectures, presentations,		
	lectures, presentations, speakers bureaus,		
	lectures, presentations, speakers bureaus, manuscript writing or		
6	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert	XNone	
6	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel	XNone	
7	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending	XNone	
7	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or	XNone	
7	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending	XNoneXNoneXNone	
7	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data	XNone	
7	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or	XNoneXNoneXNone	
7	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board	XNone XNone XNone XNone	
8	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or	XNoneXNoneXNoneXNone	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered ev	ery question and	have not altered t	the wording of an	y of the questio	ns on this
	form.						

Date: 8	3/24/2021
Your Na	me: Guisen Li
Manusc	ript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manusc	ript number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		Notional Natural Calaria	No. 91070641
		National Natural Science Foundation of China	No. 81970641
			C10040
		Sichuan Medical Research	\$18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath	
		planning Committee	2040VEC0E20
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
٥	pending	^_None	
	Penung		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	, ,,	1	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered e	every question and	have not altered t	the wording of an	y of the questic	ons on this
	form.						

Date: 8/24/2021
Your Name: Li Wang
Manuscript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN
Manuscript number (if known): APM-21-2065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104
		Science and Technology Project of Sichuan Province	2020YJ0447

		National National Calanas	No. 91070641
		National Natural Science Foundation of China	No. 81970641
			C10040
		Sichuan Medical Research	\$18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath	
		planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		he National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research	
		Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
,	Royalties of ficerises	XNone	
4	Consulting food	V None	
4	Consulting fees	XNone	
_			
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
		V N	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10		V None	
10	Leadership or fiduciary role	XNone	
	in other board, society,		

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered	every question and	l have not altered t	he wording of any	y of the question	s on this
	form.						

Date: 8/24/2021	
Your Name: Wei Wang	
Manuscript Title: HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN	
Manuscript number (if known): APM-21-2065	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone					
	Time frame: past 36 months						
2	Grants or contracts from any entity (if not indicated in item #1 above).	University of Electronic Science and Technology of China Central University Research Fund	ZYGX2019J104				
		Science and Technology Project of Sichuan Province	2020YJ0447				

		National Natural Science	No. 81970641
		Foundation of China	
		Sichuan Medical Research	S18040
		Project	1001122
		Science and Technology	19PJ132
		project of the heath planning Committee	
		the Renal Department and	2019YFS0538
		Institute of Nephrology,	20131130330
		Sichuan Provincial	
		People's Hospital,	
		University of Electronic	
		Science and Technology of	
		China, Sichuan Clinical	
		Research Center for	
		Kidney Diseases	
		the National Heart	
		Foundation Post-Doctoral	
		Fellowship	
		RACP jacquot Research Establishment Fellowship	
		Australia.	
3	Royalties or licenses	X None	
	noyanies or neerises		
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
9	Safety Monitoring Board or		
	Advisory Board		
10		X None	
10	Leadership or fiduciary role in other board, society,	XNone	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

This work was supported by a grant from the University of Electronic Science and Technology of China Central University Research Fund (ZYGX2019J104), the Science and Technology Project of Sichuan Province (2020YJ0447), the National Natural Science Foundation of China (No. 81970641), Sichuan Medical Research Project(S18040), the Science and Technology project of the heath planning Committee (19PJ132) and the Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases (2019YFS0538). Dr Amanda Y Wang is supported by the National Heart Foundation Post-Doctoral Fellowship and RACP jacquot Research Establishment Fellowship Australia.

X_	I certify that	I have answered of	every question and	have not altered t	the wording of an	y of the questic	ons on this
	form.						